血管紧张素Ⅱ2型受体A1675G基因多态性对氯沙坦降压疗效的影响
|
摘要
目的探讨原发性高血压(EH)患者血管紧张素Ⅱ2型受体(AT2R)A1675G基因多态性对氯沙坦降压疗效的影响。方法 EH患者151例,采用SnaPshot技术进行AT2R A1675G基因多态性分型。患者服用氯沙坦100mg,每天1次。随访6个月,比较各基因型或不同基因型组合之间血压下降值的差别。结果 151例中,AT2RA1675G基因AA基因型83例,AG基因型22例,GG基因型46例。治疗6个月,AA基因型患者SBP下降值(ΔSBP)大于GG基因型[(24.3±1.1)mmHg vs.(13.2±1.4)mmHg](P<0.05)。三种基因型患者的DBP和MAP也呈下降趋势,组间差异无统计学意义(P>0.05)。结论 AT2R A1675G基因多态性可能与氯沙坦的降压疗效相关,EH患者A等位基因可能是影响该药物降压效果的关键因素。
Objective To investigate the relationship of A1675 Ggene polymorphism of type 2 receptor of angiotensin Ⅱ(AT2 R)and antihypertensive efficacy of losartan in the patients with essential hypertension(EH).Methods The A1675 Ggene polymorphism of AT2 R was genotyped by Snapshot technology in 151 EH patients.The patients were treated with losartan 100 mg daily for six months.The differences in the reduction of blood pressure were compared among the patients with different A1675 Ggenotypes.Results Of 151 cases,83 cases were with AT2 RA1675 Ggene type AA,22 cases were with type AG,and 46 cases were with type GG.After 24 weeks of losartan treatment,the patients with AT2 RA1675 Gpolymorphism AA genotype showed a greater reduction in SBP than those carrying GG genotype[(24.3±1.1)mmHg vs.(13.2±1.4)mmHg](P<0.05).There was a tendency of reduction of DBP and MAP in three types of A1675 G gene,but the difference of the reduction was not significantly different among the patients with different types of A1675 G gene(P>0.05).Conclusion The A1675 G gene polymorphism of AT2 R may be related to the antihypertensive effect of losartan and the A allele may be the key factor influencing the antihypertensive efficacy of losartan.
Objective To investigate the relationship of A1675 Ggene polymorphism of type 2 receptor of angiotensin Ⅱ(AT2 R)and antihypertensive efficacy of losartan in the patients with essential hypertension(EH).Methods The A1675 Ggene polymorphism of AT2 R was genotyped by Snapshot technology in 151 EH patients.The patients were treated with losartan 100 mg daily for six months.The differences in the reduction of blood pressure were compared among the patients with different A1675 Ggenotypes.Results Of 151 cases,83 cases were with AT2 RA1675 Ggene type AA,22 cases were with type AG,and 46 cases were with type GG.After 24 weeks of losartan treatment,the patients with AT2 RA1675 Gpolymorphism AA genotype showed a greater reduction in SBP than those carrying GG genotype[(24.3±1.1)mmHg vs.(13.2±1.4)mmHg](P<0.05).There was a tendency of reduction of DBP and MAP in three types of A1675 G gene,but the difference of the reduction was not significantly different among the patients with different types of A1675 G gene(P>0.05).Conclusion The A1675 G gene polymorphism of AT2 R may be related to the antihypertensive effect of losartan and the A allele may be the key factor influencing the antihypertensive efficacy of losartan.
引文
[1]Filigheddu F,Troffa C,Glorioso N.Pharmacogenomics of essential hypertension:are we going the right way[J].Cardiovasc Hematol Agents Med Chem,2006,4(1):7-15.
[2]Arnett DK,Claas SA,Glasser SP.Pharmacogenetics of antihypertensive treatment[J].Vascul Pharmacol,2006,44(2):107-118.
[3]Jones DS,Perlis RH.Pharmacogenetics,race,and psychiatry:prospects and challenges[J].Harv Rev Psychiatry,2006,14(2):92-108.
[4]Jin JJ,Nakura J,Wu Z,et al.Association of angiotensinⅡtype 2receptor gene variant with hypertension[J].Hypertens Res,2003,26(7):547-552.
[5]寇学俊,邢艳秋,路方红,等.血管紧张素Ⅱ-2型受体A1675G基因多态性与家族性高血压的相关性研究[J].中国循环杂志,2012,27(2):87-90.
[6]Tousoulis D,Koumallos N,Antoniades C,et al.Genetic polymorphism on type 2receptor of angiotensinⅡ,modifiescardiovascular risk and systemic inflammation in hypertensive males[J].Am J Hypertens,2010,23(3):237-242.
[7]Jones A,Dhamrait SS,Payne JR,et al.Genetic variants of angiotensinⅡreceptors and cardiovascular risk in hypertension[J].Hypertension,2003,42(4):500-506.
[8]叶华茂,陈孝文,江黎明.血管紧张素受体拮抗剂和血管紧张素转换酶抑制剂与肾脏病关系[J].国外医学(泌尿系统分册),2000,20(6):259-261.
[9]Bang LE,Wiinberg N,Wachtell K,et al.Losartan versus atenolol on 24-hour ambulatory blood pressure.A life substudy[J].Blood Press,2007,16(6):392-397.
[10]吕慈,何凤慈.氯沙坦在AT2-R介导的肾血管性高血压大鼠肾脏保护功能中的作用[J].第三军医大学学报,2007,29(10):941-944.
[2]Arnett DK,Claas SA,Glasser SP.Pharmacogenetics of antihypertensive treatment[J].Vascul Pharmacol,2006,44(2):107-118.
[3]Jones DS,Perlis RH.Pharmacogenetics,race,and psychiatry:prospects and challenges[J].Harv Rev Psychiatry,2006,14(2):92-108.
[4]Jin JJ,Nakura J,Wu Z,et al.Association of angiotensinⅡtype 2receptor gene variant with hypertension[J].Hypertens Res,2003,26(7):547-552.
[5]寇学俊,邢艳秋,路方红,等.血管紧张素Ⅱ-2型受体A1675G基因多态性与家族性高血压的相关性研究[J].中国循环杂志,2012,27(2):87-90.
[6]Tousoulis D,Koumallos N,Antoniades C,et al.Genetic polymorphism on type 2receptor of angiotensinⅡ,modifiescardiovascular risk and systemic inflammation in hypertensive males[J].Am J Hypertens,2010,23(3):237-242.
[7]Jones A,Dhamrait SS,Payne JR,et al.Genetic variants of angiotensinⅡreceptors and cardiovascular risk in hypertension[J].Hypertension,2003,42(4):500-506.
[8]叶华茂,陈孝文,江黎明.血管紧张素受体拮抗剂和血管紧张素转换酶抑制剂与肾脏病关系[J].国外医学(泌尿系统分册),2000,20(6):259-261.
[9]Bang LE,Wiinberg N,Wachtell K,et al.Losartan versus atenolol on 24-hour ambulatory blood pressure.A life substudy[J].Blood Press,2007,16(6):392-397.
[10]吕慈,何凤慈.氯沙坦在AT2-R介导的肾血管性高血压大鼠肾脏保护功能中的作用[J].第三军医大学学报,2007,29(10):941-944.